AUTL Autolus Therapeutics plc
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1730463 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY168.8%
TTM net income YoY-13.9%
TTM EPS YoY-15.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin35.8%
Operating margin-159.6%
Net margin-186.4%
FCF margin-131.1%
EBITDA margin-153.1%
Returns
ROE-174.9%
ROA-43.2%
ROIC (approx.)—
Asset turnover0.23x
Leverage & solvency
Liabilities / assets94.8%
Debt / equity0.00x
Current ratio3.72x
Interest coverage-4.79x
Cash quality & payout
Operating cash flow / net income0.69x
Accruals ratio-13.5%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $75.39M | $10.12M | $1.70M | — | — |
| Cost of revenue | $96.37M | $11.39M | $0 | — | — |
| Gross profit | -$20.98M | -$1.27M | $1.70M | — | — |
| R&D expense | $117.69M | $138.44M | $130.48M | $117.35M | $110.84M |
| SG&A expense | $131.87M | $101.72M | $46.74M | $31.90M | $31.86M |
| Operating income | -$270.54M | -$241.43M | -$179.70M | -$143.41M | -$141.05M |
| Interest expense | $36.67M | $9.29M | $45.07M | $8.90M | $1.10M |
| Pretax income | -$285.56M | -$219.13M | -$208.40M | -$148.57M | -$142.04M |
| Income tax | $1.97M | $1.53M | -$19,000 | $272,000 | $58,000 |
| Net income | -$287.53M | -$220.66M | -$208.38M | -$148.84M | -$142.10M |
| EBITDA | -$262.25M | -$233.87M | -$173.14M | -$135.99M | -$132.59M |
| EPS (basic) | -1.08 | -0.86 | -1.20 | -1.57 | -1.97 |
| EPS (diluted) | -1.08 | -0.86 | -1.20 | -1.57 | -1.97 |
| Weighted avg. shares (diluted) | 266.14M | 255.16M | 173.94M | 94.99M | 72.08M |
| Balance sheet | |||||
| Cash & equivalents | $104.13M | $228.80M | $240.34M | $382.76M | $310.34M |
| Short-term investments | $196.58M | $360.64M | $0 | — | — |
| Receivables | $24.02M | $15,000 | $109,000 | $121,000 | $0 |
| Inventory | $33.21M | $4.14M | $0 | — | — |
| Current assets | $435.92M | $660.93M | $275.30M | $425.77M | $346.95M |
| PP&E, net | $63.56M | $49.55M | $34.86M | $35.21M | $33.54M |
| Intangibles | $19.81M | $12.37M | $0 | $0 | $65,000 |
| Total assets | $589.07M | $782.73M | $375.38M | $490.27M | $405.56M |
| Current liabilities | $73.44M | $60.74M | $44.74M | $46.37M | $28.55M |
| Total liabilities | $410.94M | $355.40M | $263.91M | $191.60M | $92.24M |
| Shareholders' equity | $178.13M | $427.32M | $111.47M | $298.67M | $313.32M |
| Cash flow statement | |||||
| Operating cash flow | -$283.57M | -$206.27M | -$145.59M | -$112.31M | -$117.86M |
| Capital expenditure | $19.04M | $22.07M | $10.99M | $10.84M | $8.86M |
| Free cash flow | -$302.61M | -$228.35M | -$156.57M | -$123.15M | -$126.72M |
| Investing cash flow | $158.46M | -$394.55M | -$10.99M | -$10.84M | -$8.86M |
| Financing cash flow | -$4.34M | $589.55M | -$883,000 | $223.61M | $284.06M |
| Depreciation & amortization | $8.30M | $7.55M | $6.57M | $7.42M | $8.46M |
| Stock-based compensation | $14.44M | $15.47M | $11.20M | $12.01M | $9.94M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.